Technology Expertise Keywords
Next Generation Sequencing; Transcriptomic Analyses; Liquid Biopsies
Clinical Trial Keywords
Biomarker-driven immuno-oncology clinical trials
Selected Publications
View all on PubMed
Anagnostou V, Niknafs, N, Marrone K, Bruhm D, White J, Naidoo J, Hummelink K, MOnkhorst K, Lalezari F, Lanis M, Rosner S, Reuss J, Smith K, Adleff V, Rodgers K, Belcaid Z, Rhymee L, Levy B, Feliciano J, Hann C, Ettinger D, Georgiades C, Verde F, Illei P, Li Q, Baras A, Gabrielson E, Brock M, Karchin R, Pardoll D, Baylin S, Brahmer J, Scharpf R, Forde P, Velculescu V. Multimodal Genomic Features Predict Outcome of Immune Checkpoint Blockade in Non-small Cell Lung Cancer. Nature Cancer, in press.
Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone KA, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2019 Mar 15;79(6):1214-1225.
Danilova L*, Anagnostou V*, Caushi JX, Sidhom JW, Guo H, Chan HY, Suri P, Tam A, Zhang J, Asmar ME, Marrone KA, Naidoo J, Brahmer JR, Forde PM, Baras AS, Cope L, Velculescu VE, Pardoll DM, Housseau F, Smith KN. The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunol Res. 2018 Aug;6(8):888-899. *co-first authors
Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2017 Mar;7(3):264-276
Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp P, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz Jr LA, Velculescu VE. Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation. Science Translational Medicine. 2015 Apr 15;7(283):283ra53
Patents
Immunohistochemical quantitation of tumor mTOR levels provides prognostic information on disease progression and outcome
Patent # US serial number 61/275,784 |
An objective quantitative method to predict histological subtype in non-small cell lung cancer
Patent # US serial number 13/502,079 |
A protein expression-based classifier for prediction of recurrence in lung adenocarcinomas
Patent # US serial number 61/463,715 |
Mechanisms of Acquired Resistance to Immunotherapy
Patent # US serial number 16/312,152 |
MANAFEST – A novel sensitive, specific, scalable and simple method to identify functional anti-tumor T cell responses
Patent # US serial number 62/407,820 |
Non-invasive Detection of Response to Immunotherapy
Patent # US serial number 62/657,600 |
Genomic Drivers of Response to Immunotherapy
Patent # US serial number 62/824,807 |
Matched white blood cell and cell-free DNA analyses for prediction of therapeutic response in patients with cancer
Patent # pending |
